What Is the Promise Of Embryonic Stem Cell Research?
Tags: FEDERAL aid to research; CELL lines; THERAPEUTICS
Related Articles
- American Society of Hematology New Statement and Policy. King, Cynthia R. // Oncology Nursing Forum;Jan2005, Vol. 32 Issue 1, p21
Reports on the support given by the American Society of Hematology (ASH) to stem cell research (SCR). Endorsement of ASH to efforts expanding the list of human embryonic stem cell lines that are eligible for federal research funding; Information on the policy created by the U.S. President...
- Federal funds will accelerate devil tumour disease work. // Ecos;Feb/Mar2006, Issue 129, p4
The article reports on the allocation of a federal grant to control the spread of tumor disease among Tasmanians through a concise research of counteracting the course of disease. The Commonwealth Scientific and Industrial Research Organization and Tasmanian governments combined forces in...
- Stem cells by any other name. Baker, Monya // Nature;9/27/2007, Vol. 449 Issue 7161, p389
The article reports on the announcement of the U.S. National Institutes of Health that the U.S. Human Embryonic Stem Cell Registry will change its name to Human Pluripotent Stem Cell Registry. The name change is a result from an executive order issued by President George W. Bush. The order,...
- Scientists Puzzle Over Bush's Stem Cell Decision. Webb, Marion // San Diego Business Journal;8/20/2001, Vol. 22 Issue 34, p9
Reports developments in research and therapy product development in the United States as of August 2001. Decision of President George W. Bush to omit funding for stem-cell research; Questions raised regarding the decision; Fund received by Collateral Therapeutics Inc. for the development of...
- The Politics of Testosterone. Redfearn, Suz // Men's Health (10544836);Apr2005, Vol. 20 Issue 3, p153
Reports on the decision of the U.S. National Institutes of Health to not allocate funding for a study on testosterone-replacement therapy in 2002. Cost of the research; Reason behind the decision; Comment from researcher Robert Tan on the possible prostate cancer risk associated with the therapy.
- Military gains. Gillette, Bill // Dermatology Times;Jul2008, Vol. 29 Issue 7, p25
The article reports on the a multimillion-dollar research grant awarded by the U.S. Department of Defense (DOD) to develop new therapies for wounded soldiers, which may hasten the pace at which unique, innovative burn and wound healing and cosmetic procedures become commonly used in treating...
- Differential expression and role of p21cip/waf1 and p27kip1 in TNF-a-induced inhibition of proliferation in human glioma cells. Sudheer Kumar, Pabbisetty; Shiras, Anjali; Das, Gowry; Jagtap, Jayashree C.; Prasad, Vandna; Shastry, Padma // Molecular Cancer;2007, Vol. 6, p1
Background: The role of TNF-a in affecting the fate of tumors is controversial, while some studies have reported apoptotic or necrotic effects of TNF-a, others provide evidence that endogenous TNF-a promotes growth and development of tumors. Understanding the mechanism(s) of TNF-a mediated...
- Sodium Ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Carosio, Roberta; Zuccari, Guendalina; Orienti, Isabella; Mangraviti, Salvatore; Montaldo, Paolo G. // Molecular Cancer;2007, Vol. 6, p55
Background: Neuroblastoma (NB) is an extra-cranial solid tumour of childhood. In spite of the good clinical response to first-line therapy, complete eradication of NB cells is rarely achieved. Thus, new therapeutic strategies are needed to eradicate surviving NB cells and prevent relapse. Sodium...
- Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Klopper, Joshua P.; Sharma, Vibha; Berenz, Andrew; Hays, William R.; Loi, Michele; Pugazhenthi, Umarani; Said, Sherif; Haugen, Bryan R. // Molecular Cancer;2009, Vol. 8, Special section p1
Background: Metastatic melanoma has a high mortality rate and suboptimal therapeutic options. Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid x receptor selective agonist, and thiazolidinediones (TZD), PPAR? selective ligands, as novel treatments. Results: Mouse...
